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Background. Ketamine sedation has been found superior by physician report to traditional sedation regimens for pediatric
endoscopy. Goal. To objectively compare sedation with ketamine versus midazolam/fentanyl for children undergoing
gastrointestinal endoscopy. Study. Patients received one of two regimens and were independently monitored using a standardized
ratingscale.Results.There were2episodes oflaryngospasmduringketaminesedation.Univariateanalysesshowedpatients sedated
with ketamine (n = 17) moved more (median 25% of procedure time versus 8%, P = .03) and required similar low levels of
restraint(0.83%versus0.25%, P = .4)aspatients sedated withmidazolam/fentanyl(n = 20).Age-adjusted analysessuggested that
patientssedated withketaminewere comparablymorequiet (P = .002).Conclusions.Apilottrialofketamineatourinstitutionwas
associated with episodes of laryngospasm. In addition, children sedated with ketamine moved and required restraint similarly to
patients sedated with midazolam/fentanyl. Physician perceptions may be aﬀected by the fact that children who received ketamine
were less likely to vocalize distress.
1.Introduction
Moderate sedation is deﬁned as a level of consciousness at
which pain is successfully diminished, while the abilities to
maintain a patent airway and to respond to light stimuli are
maintained [1]. While many pediatric endoscopists report
performing all of their procedures with general anesthesia,
approximately a third continue to report administering
moderate sedation [2] using a variety of endoscopist-
administered sedation regimens [3, 4]. Many institutions
use a sedation regimen that combines a narcotic with a
benzodiazepine. More recently, ketamine has been suggested
as a preferred regimen—both in terms of its safety and eﬀect-
iveness [5–8].
Comparisons of sedation regimens for endoscopy are
fundamentally dependent upon clear outcome measures.
Whereas safety of sedation can be quantitatively determined
by measuring adverse events, assessing the eﬀectiveness of
sedation has been less clearly deﬁned. Historically, eﬀec-
tiveness of sedation for children undergoing endoscopy
has been described either in terms of successful procedure
completion, or has been based upon subjective staﬀ ratings
of intraprocedural sedation adequacy [4, 7]. Neither of
these measures fully account for immobilization and patient
cooperation as ideal outcomes of sedation [8].
Indeed, while many children tolerate moderate sedation
and undergo GI procedures safely, some can become quite
agitated despite adequate dosing of sedatives. Children who
are not eﬀectively sedated may struggle, vocalize distress,
and require manual restraint [5]. The risks of GI procedures
in uncooperative or moving patients are considerable and
include perforation of the intestinal tract and hemorrhage
[9, 10]. While restraint can be used to keep patients safe, it is
considered psychologically harmful to children [11].2 International Journal of Pediatrics
Prior studies of ketamine sedation for pediatric gastroin-
testinal endoscopy have been retrospective in nature, and
have used chart review to identify any clinical concerns for
inadequate sedation [7, 8]. The aim of our prospective study
was to pilot the use of ketamine at our institution using
independent monitors and a standardized behavioral rating
scale to formally compare it with our institutional standard
sedation regimen ofmidazolam+ fentanyl. Althoughhuman
subject protection concerns precluded randomization of
patients to sedation arms, we hypothesized that selection
biases inherent in this quality research study would favor
the ketamine arm, as physicians would speciﬁcally have
requested ketamine for those patients they felt would be
better sedated with it. Accepting that bias as unavoidable,
we sought to conﬁrm the hypothesis that patients receiving
ketamine would move less, vocalize distress less, and require
less restraint by clinical staﬀ during GI procedures than
patients receiving standard sedation with midazolam and
fentanyl. A secondary aim was to compare the safety of these
two common regimens.
2.Methods
With approval from our hospital’s Sedation Committee to
pilot the use of ketamine in our unit in approximately 15–
20 patients, we prospectively studied a convenience cohort
of children referred for endoscopy at Children’s Hospital
Boston between March 2006 and July 2007 with Institutional
Review Board approval. Patients were evaluated and a seda-
tion regimen was selected based on the clinical judgement of
their gastroenterologists at the time of procedural schedul-
ing. Appropriate informed consents for the procedure and
the study were obtained on the day of endoscopy.
Per institutional protocol, all patients were sedated to
achieve a goal depth of moderate sedation (Ramsay Level
4). Per study protocol, all patients who received ketamine
were administered an initial 1mg/kg bolus dose of ketamine
(max dose 70mg), followed by a maximum of 2 additional
bolus doses administered as necessary every 5 minutes. The
comparison group was comprised of a convenience sample
of patients who received our unit’s more standard moderate
sedation regimen of midazolam (0.05–0.3mg/kg IV, max
dose 15mg, every 3 minutes) and fentanyl (1–5μ/kg, max
dose 250μ,e v e r y5m i n u t e s ) .
In both study groups, sedation was actively administered
by credentialed gastroenterologists. Midazolam/fentanyl was
administered or supervised by one of ﬁve diﬀerent attending
gastroenterologists who performed such cases during the
study period. All ketamine sedation cases were performed
by a single endoscopist (VF), with observation by a staﬀ
anaesthesiologist (SZ) who was also in the procedure
room. Procedures in both arms were also attended by two
nurses educated in sedation pharmacology. In addition,
independent monitors measured patient movements, need
for restraint and vocalization of distress using the Ohio State
University Behavioral Rating Scale (OSUBRS)[12].
The OSUBRS is a unique monitoring tool of sedation
tolerability that has been shown to have excellent reliability
and validity in children undergoing gastrointestinal proce-
dures [13]. The distinct advantage of the OSUBRS over
otheravailablebehavioralscalesusedinmonitoringpediatric
sedation is that it allows for continuous measurement of the
tolerability of sedation throughout the duration of a proce-
dure [12]. The OSUBRSuses a computerprogramtocapture
mutually exclusive classiﬁcations of behavior (e.g., crying
versus being quiet)that are recorded continuously overtime.
Medical training is not required to use the rating scale, nor is
knowledge of sedation or procedural technicalities [14–16].
For this study, an independent monitor trained to use
the OSUBRSrating scale was present during each procedure.
The monitor sat at a computerand pressed speciﬁc letters on
a keyboard (e.g., “A” for quiet, nonmoving, nonrestrained,
“F” for vocalizing distress, moving, restrained) to record
the behavioral states over the course of the procedure
(Figure 1). An internal clock recorded the length of each
behavioral state aswell asthe overall length ofthe procedure.
Following each procedure, a study coordinator recorded
the total sedative dosage, depth of sedation, duration of
sedation, duration of the procedure, and any observed
intraprocedural adverse events from the medical record. In
addition, the study coordinator reviewed charts for clinical
documentationsuggesting inadequatesedation,as consistent
with methodology used in prior literature.
2.1. Statistical Analysis. We performed an intention-to-treat
analysis. OSUBRS outcomes were calculated as the percent-
age of overall procedure time a patient was observed vocal-
izing, moving, or requiring restraint (Figure 1). There are 6
unique combinations of states: 3 classiﬁcations of movement
(no movement, unrestrained movement, retrained move-
ment) × 2 classiﬁcations of vocalization (yes/no). Due to
the skewed nature of the outcomes, continuous data are
presented as median (IQR) and two-group comparisons
use the Wilcoxon rank-sum test. Categorical variables are
presented as N (%), and group comparisons are tested with
the Pearson χ2 statistic if all expected cell-counts are ≥5, and
Fisher’s exact test otherwise.
Analysis of covariance was used to determine covariates
independently associated with each outcome. Covariates
under consideration included type of sedation, age, gender,
American Society of Anesthesiology (ASA)class, and weight.
Age and weight were highly correlated, and therefore not
included in any model simultaneously. Since gender was
not statistically signiﬁcant in any model and weight had
aw e a k e re ﬀect than age, all models include only type of
sedation and age at the time of the procedure. An interaction
between type of sedation and age was modeled to determine
if there were diﬀerential eﬀects for sedation type by age. For
outcomes that were skewed, the Blom normal score from
the ranked data, yi =
Φ−1(ri − 3/8)/(n +1 /4), was used as
a normalizing function. Diagnostics to check the ﬁt of the
model included a histogram of the residuals and plots of
the residuals against the predicted values and each covariate
included in the model. The results for the rank-transformed
and nonranked outcomes were similar, and therefore only
the latter are reported.
All tests were two-sided and conducted at the 0.05 level
of signiﬁcance. Data analyses for this paper were generatedInternational Journal of Pediatrics 3
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Figure 1: Explanation of variables in the Ohio State University Behavioral Rating Scale (OSUBRS).
using SAS/STAT software, Version 9.1 of the SAS System
for Windows, SAS Institute Inc., Cary, NC, and SPSS for
Windows, Release 14.0, 2005, Chicago, IL.
3.Results
A total of 17 children were selected by their physicians to
receive ketamine sedation during the pilot study period.
Their data was compared with a cohort of 20 children
who received midazolam/fentanyl. Patient characteristics
reﬂected the selection bias inherent in the study and showed
the two study groups were not similar with respect to patient
characteristics (Table 1). Median age and weight of children
who received ketamine sedation was less than half that of
children in the midazolam/fentanyl group (P = .004 and
P = .005, resp.). Furthermore, the proportion of male
gender in the ketamine group (76%) was higher than in the
midazolam/fentanyl group (45%; P = .052). Similarly, the
rate of colonoscopy in the ketamine group (47%) was more
thandoublethatofthemidazolam/fentanyl group(20%;P =
.003). ASA physical status classiﬁcation scores were similar
across patient groups, with 86% of patients documented
as class I (normal healthy patient) and the remaining 14%
documented as class II (mild systemic disease).
Medicalhistorieswere similaracrosspatientgroups(data
not shown). The most common conditions noted were
abdominal pain (38%), followed by respiratory ailments
(24%; 7/9 with asthma), allergies (22%), head/ears/eyes/
nose/throat ailments (22%), and gastroesophageal reﬂux
disease (22%). Thirty percent of children were taking medi-
cation for reﬂux, and 16% were taking laxatives regularly at
the time of the sedated procedure.
Esophagogastroduodenoscopy (EGD) accounted for
more than half (68%) of all gastrointestinal procedures
Table 1: Results: Patient demographics by sedation regimen.
Paient descriptives Ketamine M/F
(N = 17) (N = 20)
Age (years), median (IQR) 5.0 (2.5, 6.5) 12.5 (6.3, 15.8)
Gender male n (%) 13 (77) 9 (45)
Race (white, non-Hispanic) n (%) 11 (65) 17 (85)
Type of procedure n (%)
EGD 9 (53) 16 (80)
Colonoscopy 7 (41) 0 (0)
EGD/colonoscopy 1 (6) 4 (20)
Weight (kg), median (IQR) 19 (13.7, 23.2) 44 (22.4, 61.4)
ASA level n (%)
I (healthy) 14 (82) 18 (90)
II (mild systemic disease) 3 (18) 2 (10)
performed in this study; all other procedures were either
colonoscopy (19%) or combined EGD/colonoscopy (14%).
There was no statistical diﬀerence in procedure times
between the two study groups. Mean sedation time was
34 ± 16 minutes for procedures that took 19 ± 14 minutes
on average to perform.
3.1. Safety. Two patients receiving ketamine sedation for
upper endoscopy were documented to experience laryn-
gospasm during their procedures. The ﬁrst case was a 3-
year-old male with abdominal pain and a history of anxiety,
undergoing an upper endoscopy for a question of Celiac
disease. Two 1mg/kg boluses of ketamine were administered
with a 5 minute interval between doses. The endoscope
was introduced, and 4 minutes later the patient experienced
laryngospasm, as detected by capnography, as well as oxygen4 International Journal of Pediatrics
Table 2:Median percent timespent by patients receiving either midazolam/fentanylorketaminesedation in each behavioralstate (N = 37).
OSUBRS measure Behavioral state Midazolam/fentanyl Ketamine P∗
Median, (IQR) Median, (IQR)
Range Range
A Nonvocalizing,nonmoving,
nonrestrained
90.1 (67.7, 97.8)
17.8–99.9
74.5 (62.8, 85.8)
46.2–99.4 .067
B Nonvocalizing,moving, nonrestrained 4.5 (1.7, 8.4)
0–30.9
11.7 (5.6, 21.7)
0–40.4 .023
C Nonvocalizing,moving, restrained 0.2 (0, 1.6)
0–30.1
0.8 (0, 8.5)
0–46.4 .302
D Vocalizing,nonmoving, nonrestrained 0.6 (0.1, 3.4)
0–41.0
0 (0, 2.6)
0–7.6 .180
E Vocalizing,moving, nonrestrained 0.7 (0, 2.8)
0–13.7
1.1 (0, 3.8)
0–11.2 .609
F Vocalizing,moving, restrained 0 (0, 0.6)
0–34.2
0 (0, 1.0)
0–6.4 .893
∗Wilcoxon rank-sum test.
desaturation to less than 90% SpO2. In response, an
oral airway was placed, positive pressure ventilation was
performed and the procedure was aborted. The second case
oflaryngopasminvolveda7-year-oldfemalewithcomplaints
of dysphagia and a distant history of mild asthma who
was scheduled to undergo upper endoscopy. A 30mg/kg
bolus of ketamine was administered to good sedation eﬀect.
The procedure was started and within 3 minutes halted
due to laryngospasm and oxygen desaturation to a SpO2
of 50%. Positive pressure ventilation with was administered
with return to full spontaneous ventilation and a normal
oxygen saturation of 100%. The procedure was subsequently
restarted and completed successfully.
3.2. Sedation Eﬀectiveness. No patient charts reviewed in
the study were noted to have documentation suggesting
inadequate sedation to perform endoscopy, and all were
documented to achieve institutional goal depth of sedation.
In terms of prospective measurements, unadjusted analysis
showed neither sedation type was strongly associated with
vocalization or need for restraint (Table 2). Vocalization
accounted for only a median 2.5% of procedural time (IQR
0.3–9.7%), while physical restraint was required just 0.5%
of procedural time (IQR 0.0–6.7%). Patients sedated with
ketamine did however move their arms, bodies, and legs
more than those sedated with midazolam/fentanyl (median
25% of procedure time versus 8% of procedure time,
P = .03).
After adjusting for age, there was no diﬀerence between
the two sedation types with respect to patient movement,
with older patients tending to move less than younger
patients, independent of sedation type (P = .02). Increased
age was also associated with more time nonvocalizing
regardless of sedation type (P = .001). In an age-adjusted
analysis (see Figure 2), ketamine sedation was associated
with a greater percentage of time nonvocalizing across all
ages compared with midazolam/fentanyl (P = .002).
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Figure 2: Analysis of covariance of percent time nonvocalizing
on years of age, adjusted for sedation type. Ketamine sedation
is represented by closed circles (•) and a solid regression line
(—) while medazolam/fentanyl is represented by open circles (◦)
andadottedregressionline(...).Ketaminesedationisassociated
with a greater percentage of time nonvocalizing compared with
medazolam/fentanyl (P = .002), independent of the eﬀect of age.
The interaction of sedation type with age was not statistically
signiﬁcant (P = .31).
4.Discussion
The primary aim of our pilot study was to formally
and prospectively compare the eﬀectiveness of moderate
sedation with ketamine for gastrointestinal endoscopy in
children with that of more commonly used regimens com-
bining benzodiazepines and opioids. To a great extent, this
study was undertaken with the expectation that piloting
ketamine in our endoscopy unit with an eye to quality
and safety would reveal ketamine to be superior to our
current standard of midazolam and fentanyl. We acceptedInternational Journal of Pediatrics 5
a patient-selection bias, and indeed our results show that
independentofage,pediatricpatientswhoreceivedketamine
were less likely to vocalize distress than those adminis-
tered midazolam/fentanyl. On the other hand, we also
found that ketamine was associated with increased (not
decreased) body movement and the same need for restraint
by clinical staﬀ as children receiving midazolam/fentanyl.
Such results are useful for clarifying a discussion of the
comparative eﬀectiveness of these two sedation regimens for
endoscopy.
Patients in our study were administered a particular
sedative based on physician judgement. In general, we
found that physicians were more likely to refer younger
children for ketamine, perhaps based on a perception that
midazolam/fentanyl does not adequately provide sedation in
thisagegroupandthatketaminewouldbemoreeﬀective.We
believe such selection biases should have favored the eﬀects
of ketamine. Instead, we found that patients who received
ketamine required restraint for equal percentages of proce-
dure time as their peers who received midazolam/fentanyl.
A secondary aim of our study was to examine sedation
safety, at least in terms of intraprocedural events. In our
small study, there were two patients who experienced
laryngospasm in the ketamine group versus no patients with
adverse events in the midazolam/fentanyl group. Although
ketamine has been deemed safe based on its cardiovas-
cular and respiratory protective eﬀect [8, 17–19], it is
also associated with increased risk of laryngospasm [7, 20,
21]. Both episodes of laryngospasm in our study occurred
during upper endoscopic procedures, where stimulation
of the posterior pharynx may increase risk of airway
complications.
Our pilot work objectively assesses and compares eﬀec-
tiveness of sedation regimens for children undergoing endo-
scopic procedures using independent monitoring and a
standardized, continuous, behavioral rating scale. Previous
reports in dental and oncology populations have used
global ratings by clinicians to state that ketamine reduces
behavioral distress [22], increases patient cooperation [23],
and reduces crying and body movements [24, 25]. In
contrast, the independently obtained observations in our
study are consistent with the fact that ketamine sedation
increases muscular hypertonicity and stereotypical “random
movements” in children [26], leading to use of restraint. The
discrepancies between our investigation and prior reports
are most likely due to a previous lack of standardized
and objective behavioral scoring methods in head-to-head
comparisons of the eﬀectiveness of sedation regimens for
gastrointestinal endoscopy. We believe the use of continuous
measures over the duration of a procedure may ultimately
allow a clearer deﬁnition of eﬀectiveness as a descriptor of
sedation regimens.
The Ohio State University Behavioral Scale (OSUBS)
used in this study has been previously shown to be a
reliable method for evaluating behaviour in sedated children
undergoing dental procedures [16, 27], and has been vali-
dated by our group in children undergoing gastrointestinal
procedures [13]. In turn, eﬀectiveness of sedation can be
operationalized according to the OSUBRS. In particular, it
may be plausible to deﬁne optimally eﬀective sedation as
rendering a patient “quiet, still, and unrestrained”; while a
patient who is “vocalizing distress, moving, and restrained”
is least eﬀectively sedated. The use of the OSUBRS also
allows measurement of the tendency for patients to move
back and forth between behavioral states, as the eﬀects of
the medications, their underlying anxiety, and the stimulus
o ft h ep r o c e d u r ev a r yo v e rt i m e .
There are a number of limitations to the present study
that should be considered, in addition to the most important
concern that the study was not randomized. In particular,
the pilot nature of this study precluded adequate sample
size calculations, the sample sizes analyzed were small, and
study groups were unequal with regards to patient age and
procedure type. Patients receiving ketamine were overall
younger (median age of5 years) and more likelyto be under-
going colonoscopy compared to the fentanyl/midazolam
group (median age of 12.5 years). The small sample size
also precludes a true discussion of safety. Our pilot data
may be useful for planning larger studies required to deter-
mine whether laryngospasm or other adverse events occurs
more frequently with ketamine than has been reported
previously.
Another possible limitation of this study was that it used
relatively broad-based deﬁnitions of “moving” and “needing
restraint”. Moving in the present study included both
intentional (combative) and unintentional (drug-induced)
movement. Nonetheless, regardless of reason for restraint
or forcefulness of restraint, the number of staﬀ needed for
the procedure to be safely conducted remained unchanged.
Ketamine, therefore, may not aﬀord advantages for pediatric
endoscopy in terms of reducing staﬀ or resources.
A ﬁnal aspect not considered here, but worthy of
investigation are more long-term adverse events associated
with ketamine, as a dissociative and hallucinogenic agent.
Ketamine has been observed to induce a “locked-in” state,
which may prevent patients from vocalizing distress, but
allow them to witness their procedure. Future studies might
consider sending patients home with a diary to document
their experiences after their procedure under ketamine.
In conclusion, fentanyl/midazolam is a standard sedative
regimen commonly used for GI procedures that is not totally
reliable at rendering patients quiet and nonmoving. More
recently, a number of studies have suggested that ketamine
may provide superior and equally safe pediatric sedation
[8,19,26,28,29].Althoughpatientsinourprospective study
were less likely to vocalize distress, they were still likely to
move and require restraint during procedures. In addition,
our study found ketamine sedation to be more associated
with laryngospasm during pediatric endoscopy, which has
currently limited our interest in using it further in our
unit. Our study demonstrates that eﬀective sedation relies
on numerous factors and may not be adequately measured
by global postprocedural ratings. With the use of objective
and continuous behavioral measurements, key diﬀerences in
the eﬀectiveness of diﬀerent sedation regimens for gastroin-
testinal endoscopy will become clearer and guidelines for
improvements in pediatric sedation more likely.6 International Journal of Pediatrics
References
[1] American Society of Anesthesiology, Distinguishing Monitored
Anesthesia Care (“MAC” from Moderate Sedation/Analgesia
(Conscious Sedation)),vol.2005,The ASA Houseof Delegates,
2004.
[ 2 ]J .R .L i g h t d a l e ,L .B .M a h o n e y ,S .M .S c h w a r z ,a n dC .A .
Liacouras, “Methods of sedation in pediatric endoscopy:
as u r v e yo fN A S P G H A Nm e m b e r s , ”Journal of Pediatric
Gastroenterology and Nutrition, vol. 45, no. 4, pp. 500–502,
2007.
[ 3 ]L .B .M a h o n e ya n dJ .R .L i g h t d a l e ,“ S e d a t i o no ft h ep e d i a t r i c
and adolescent patient for GI procedures,” Current Treatment
Options in Gastroenterology, vol. 10, no. 5, pp. 412–421, 2007.
[ 4 ] V .T o l i a ,J .M .P e t e r s ,a n dM .A .G i l g e r ,“ S e d a t i o nf o rp e d i a t r i c
endoscopic procedures,” Journal of Pediatric Gastroenterology
and Nutrition, vol. 30, no. 5, pp. 477–485, 2000.
[5] M. E. Fredette and J. R. Lightdale, “Endoscopic sedation in
pediatric practice,” Gastrointestinal Endoscopy Clinics of North
America, vol. 18, no. 4, pp. 739–751, 2008.
[6] P. Mamula, J. E. Markowitz, K. Neiswender et al., “Safety
of intravenous midazolam and fentanyl for pediatric GI
endoscopy: prospective study of 1578 endoscopies,” Gastroin-
testinal Endoscopy, vol. 65, no. 2, pp. 203–210, 2007.
[ 7 ]M .A .G i l g e r ,R .S .S p e a r m a n ,C .L .D i e t r i c h ,G .S p e a r m a n ,
M. J. Wilsey Jr., and M. N. Zayat, “Safety and eﬀectiveness
of ketamine as a sedative agent for pediatric GI endoscopy,”
Gastrointestinal Endoscopy, vol. 59, no. 6, pp. 659–663, 2004.
[ 8 ]S .M .G r e e n ,M .K l o o s t e r ,T .H a r r i s ,E .L .L y n c h ,a n dS .G .
Rothrock, “Ketamine sedation for pediatric gastroenterology
procedures,” Journal of Pediatric Gastroenterology and Nutri-
tion, vol. 32, no. 1, pp. 26–33, 2001.
[9] R. Hart and M. Classen, “Complications of diagnostic gas-
trointestinal endoscopy,” Endoscopy, vol. 22, no. 5, pp. 229–
233, 1990.
[10] V. L. Fox, “Clinical competency in pediatric endoscopy,”
Journal of Pediatric Gastroenterology and Nutrition, vol.26,no.
2, pp. 200–204, 1998.
[11] R. D. Pitetti, S. Singh, and M. C. Pierce, “Safe and eﬃcacious
use of procedural sedation and analgesia by nonanesthesi-
ologists in a pediatric emergency department,” Archives of
Pediatrics and Adolescent Medicine, vol. 157, no. 11, pp. 1090–
1096, 2003.
[12] S. Wilson, “A review of important elements in sedation study
methodology,” Pediatric Dentistry, vol. 17, no. 7, pp. 406–412,
1995.
[13] J. R. Lightdale, L. Scharﬀ,N .F .S e t h n a ,L .A .H e a r d ,K .M .
Donovan, and V. L. Fox, “Validation of a continuous measure
of sedation in children undergoing endoscopy,” Journal of
Pediatric Gastroenterology and Nutrition, vol. 35, no. 3, p. 438,
2002.
[14] S.Wilson,A. Matusak,P. S.Casamassimo,and P. Larsen,“The
eﬀects of nitrous oxide on pediatric dental patients sedated
withchloralhydrate andhydroxyzine,”Pediatric Dentistry,v ol.
20, no. 4, pp. 253–258, 1998.
[15] S. Wilson, L. de Lourdes Molina, J. Preisch, and J. Weaver,
“The eﬀect of electronic dental anesthesia on behavior during
localanestheticinjection intheyoung,sedated dentalpatient,”
Pediatric Dentistry, vol. 21, no. 1, pp. 12–17, 1999.
[16] W. McCann, S. Wilson, P. Larsen, and B. Stehle, “The eﬀects
of nitrous oxide on behavior and physiological parameters
during conscious sedation with a moderate dose of chloral
hydrate and hydroxyzine,” Pediatric Dentistry,v o l .1 8 ,n o .1 ,
pp. 35–41, 1996.
[17] S.M.G r e e n,T .K .D e nmar k,J .C line ,C .R oghair ,S.A b dA llah,
and S. G. Rothrock, “Ketamine sedation for pediatric critical
care procedures,” Pediatric Emergency Care, vol. 17, no. 4, pp.
244–248, 2001.
[18] P. F. White, L. O. Vasconez, S. A. Mathes, W. L. Way, and
L. A. Wender, “Comparison of midazolam and diazepam for
sedation during plastic surgery,” Plastic and Reconstructive
Surgery, vol. 81, no. 5, pp. 703–710, 1988.
[19] D. L. Reich and G. Silvay, “Ketamine: an update on the ﬁrst
twenty-ﬁve years of clinical experience,” Canadian Journal of
Anaesthesia, vol. 36, no. 2, pp. 186–197, 1989.
[20] R. S. Spearman, G. Spearman, M. J. Wilsey Jr., and M. Gilger,
“Is Ketamine a “safe” sedative agent for pediatric endoscopy?”
Journal of Pediatric Gastroenterology and Nutrition, vol. 31, p.
S29, 2000.
[ 2 1 ]A .A g g a r w a l ,S .G a n g u l y ,V .K .A n a n d ,a n dA .K .P a t w a r i ,
“Eﬃcacy and safety of intravenous ketamine for sedation
and analgesiaduring pediatric endoscopicprocedures,” Indian
Pediatrics, vol. 35, no. 12, pp. 1211–1214, 1998.
[ 2 2 ]C .M .M a r x ,J .S t e i n ,M .K .T y l e r ,M .L .N i e d e r ,S .B .S h u r i n ,
and J. L. Blumer, “Ketamine-midazolam versus meperidine-
midazolam for painful procedures in pediatric oncology
patients,” Journal of Clinical Oncology, vol. 15, no. 1, pp. 94–
102, 1997.
[23] K. Rai, A. M. Hegde, and K. Goel, “Sedation in uncooperative
children undergoing dental procedures: a comparative evalua-
tionofmidazolam,propofolandketamine,”Journal of Clinical
Pediatric Dentistry, vol. 32, no. 1, pp. 1–4, 2007.
[ 2 4 ]E .C .A l f o n z o - E c h e v e r r i ,J .H .B e r g ,T .W .W i l d ,a n dN .L .
Glass, “Oral ketamine for pediatric outpatient dental surgery
sedation,”Pediatric Dentistry,vol.15,no.3,pp.182–185,1993.
[25] T. Bui, R. J. Redden, and S. Murphy, “A comparison study
between ketamine and ketamine-promethazine combination
for oral sedation in pediatric dental patients,” Anesthesia
Progress, vol. 49, no. 1, pp. 14–18, 2002.
[26] S. M. Green, R. Nakamura, and N. E. Johnson, “Ketamine
sedation for pediatric procedures—part 1: a prospective
series,” Annals of Emergency Medicine,vol. 19, no. 9, pp. 1024–
1032, 1990.
[27] M. E. Lochary, S. Wilson, A. L. Griﬀen, and D. L. Coury,
“Temperament as a predictor of behavior for conscious
sedation in dentistry,” Pediatric Dentistry,v o l .1 5 ,n o .5 ,p p .
348–352, 1993.
[28] J. Proudfoot, “Analgesia, anesthesia, and conscious sedation,”
EmergencyMedicineClinicsofNorth America, vol.13,no.2,pp.
357–379, 1995.
[29] S. M. Auden, W. L. Sobczyk, R. E. Solinger, and L. J.
Goldsmith, “Oral ketamine/midazolam is superior to intra-
muscular meperidine, promethazine, and chlorpromazine for
pediatric cardiac catheterization,” Anesthesia and Analgesia,
vol. 90, no. 2, pp. 299–305, 2000.